Share-based Payment Arrangement, Expense of TherapeuticsMD, Inc. from 31 Dec 2012 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
TherapeuticsMD, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Jun 2025.
  • TherapeuticsMD, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $1,000.
  • TherapeuticsMD, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,300,000, a 89% decline from 2022.
  • TherapeuticsMD, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11,600,000, a 36% decline from 2021.
  • TherapeuticsMD, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $18,100,000, a 69% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

TherapeuticsMD, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $1,000* -$95,000 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q3 2024 $33,000 -$167,000 -84% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $96,000 -$304,000 -76% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q4 2023 $1,300,000 $200,000 -$2,800,000 -93% 01 Oct 2023 31 Dec 2023 10-K 29 Mar 2024 2023 FY
Q3 2023 $4,100,000 $200,000 -$4,100,000 -95% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $8,200,000 $400,000 -$1,800,000 -82% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $10,000,000 $500,000 -$1,600,000 -76% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $11,600,000 $3,000,000 -$2,300,000 -43% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $13,900,000 $4,300,000 -$3,000,000 -41% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $16,900,000 $2,200,000 -$300,000 -12% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $17,200,000 $2,100,000 -$900,000 -30% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $18,100,000 $5,300,000 01 Oct 2021 31 Dec 2021 10-K 07 Apr 2023 2022 FY
Q3 2021 $7,300,000 +$4,200,000 +135% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $2,500,000 -$500,000 -17% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $3,000,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $3,100,000 +$905,333 +41% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $3,000,000 +$769,171 +34% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q4 2019 $10,700,000 $4,131,265 +$2,021,313 +96% 01 Oct 2019 31 Dec 2019 10-K 23 Mar 2022 2021 FY
Q3 2019 $8,678,687 $2,194,667 +$85,449 +4.1% 01 Jul 2019 30 Sep 2019 10-Q 08 Nov 2019 2019 Q3
Q2 2019 $8,593,238 $2,230,829 +$18,588 +0.84% 01 Apr 2019 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 $8,574,650 $2,143,239 +$483,356 +29% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 $8,091,294 $2,109,952 +$354,533 +20% 01 Oct 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
Q3 2018 $7,736,761 $2,109,218 +$224,168 +12% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $7,512,593 $2,212,241 +$706,616 +47% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $6,805,977 $1,659,883 +$358,823 +28% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $6,447,154 $1,755,419 -$2,089,717 -54% 01 Oct 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
Q3 2017 $8,536,871 $1,885,050 -$2,097,709 -53% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $10,634,580 $1,505,625 -$2,654,446 -64% 01 Apr 2017 30 Jun 2017 10-Q 30 Jul 2018 2018 Q2
Q1 2017 $13,289,026 $1,301,060 -$2,850,199 -69% 01 Jan 2017 31 Mar 2017 10-Q 07 May 2018 2018 Q1
Q4 2016 $16,139,225 $3,845,136 +$1,552,441 +68% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $14,586,784 $3,982,759 +$2,355,897 +145% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $12,230,887 $4,160,071 +$2,186,396 +111% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $10,044,491 $4,151,259 +$3,422,833 +470% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q4 2015 $6,621,658 $2,292,695 +$1,240,844 +118% 01 Oct 2015 31 Dec 2015 10-K 23 Feb 2018 2017 FY
Q3 2015 $5,380,814 $1,626,862 +$579,369 +55% 01 Jul 2015 30 Sep 2015 10-Q 05 Nov 2015 2015 Q3
Q2 2015 $4,801,445 $1,973,675 +$685,589 +53% 01 Apr 2015 30 Jun 2015 10-Q 07 Aug 2015 2015 Q2
Q1 2015 $4,115,856 $728,426 -$277,599 -28% 01 Jan 2015 31 Mar 2015 10-Q 07 May 2015 2015 Q1
Q4 2014 $4,393,455 $1,051,851 01 Oct 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
Q3 2014 $1,047,493 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2014 $1,288,086 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $1,006,025 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1

TherapeuticsMD, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $1,300,000 -$10,300,000 -89% 01 Jan 2023 31 Dec 2023 10-K 29 Mar 2024 2023 FY
2022 $11,600,000 -$6,500,000 -36% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $18,100,000 +$7,400,000 +69% 01 Jan 2021 31 Dec 2021 10-K 07 Apr 2023 2022 FY
2020 $10,700,000 $0 0% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
2019 $10,700,000 +$2,608,706 +32% 01 Jan 2019 31 Dec 2019 10-K 23 Mar 2022 2021 FY
2018 $8,091,294 +$1,644,140 +26% 01 Jan 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
2017 $6,447,154 -$9,692,071 -60% 01 Jan 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
2016 $16,139,225 +$9,517,567 +144% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $6,621,658 +$2,228,203 +51% 01 Jan 2015 31 Dec 2015 10-K 23 Feb 2018 2017 FY
2014 $4,393,455 +$1,192,800 +37% 01 Jan 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
2013 $3,200,655 +$1,368,594 +75% 01 Jan 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
2012 $1,832,061 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.